GlassScriptPhysician profile
Walter Steven Trombold
NPI 1023027281
$2,920.90
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $248 · 2021: $90.29 · 2022: $381 · 2023: $789 · 2024: $66.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.98 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $444.84 | 2019-2023 | Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $381.93 | 2019-2023 | Breztri, Fasenra, Tezspire |
| United Therapeutics Corporation | $314.83 | 2019-2023 | Tyvaso, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.97 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $156.45 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $156.37 | 2019-2023 | Xolair, Esbriet |
| Actelion Pharmaceuticals US, INC. | $140.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $137.17 | 2019-2024 | |
| Pfizer INC. | $118.38 | 2019-2023 | |
| Grifols USA, LLC | $95.34 | 2019-2023 | Prolastin-C Liquid, Xembify |
| Csl Behring | $94.97 | 2022-2024 | Kcentra |
| Abbvie INC. | $81.68 | 2022-2023 | Avycaz |
| Circassia INC. | $79.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.68 | 2019-2024 | Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $56.90 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $55.37 | 2022-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $40.91 | 2022-2023 | Purified Cortrophin Gel |
| Philips North America LLC | $40.04 | 2019-2023 | |
| Amgen INC. | $37.93 | 2022-2023 | Tezspire |
| Janssen Pharmaceuticals, INC | $36.16 | 2019 | |
| Insmed, INC. | $35.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.12 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $32.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $25.28 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.76 | 2022 | |
| Electromed, INC. | $20.27 | 2019 | |
| Pulmonx Corporation | $13.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Trombold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.